Acrux in dire need of booster shot

Acrux suffered its worst sell-off in 14 months on a disappointing sales update on its flagship testosterone treatment drug.

Acrux (ACR) suffered its worst sell-off in 14 months on a disappointing sales update on its flagship testosterone treatment drug.

{{content.question}}

SMS Code Sent…

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa

Related Articles